Kidney Cancer

Phase 3 LITESPARK-011 trial results demonstrated PFS and ORR benefits with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC after ICI therapy.

When patients with RCC progress on a TKI/IO combination, advanced practice providers use patient experience to inform treatment decisions.

Margarita Huober, AGNP, AOCNP, explains that understanding a patient on an individual level leads to more informed care decisions in RCC.

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.

ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.

A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.

The subcutaneous formulation of nivolumab showed comparable efficacy and safety to the IV formulation in advanced clear cell renal cell carcinoma.

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.

Patient-reported outcomes were consistent between patients with RCC using tivozanib/nivolumab and tivozanib monotherapy according to study findings.

Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine showed no recurrence at data cutoff.

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion center.

Frontline treatment with belzutifan and cabozantinib resulted in durable responses and a manageable safety profile in patients with previously untreated advanced ccRCC.

Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) was approved by the FDA for subcutaneous injection across approved solid tumor indications for nivolumab (Opdivo).

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma.

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert said.

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated advanced renal cell carcinoma.

Compared to sunitinib, nivolumab plus ipilimumab showed increased overall survival and durable response benefits in patients with advanced renal cell carcinoma.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.

Nivolumab plus tivozanib did not improve progression-free survival in patients with advanced metastatic renal cell carcinoma after prior immune checkpoint inhibition.